-
Product Insights
APE/ Cores Dev/ Foresite/ Urbicoon – Royale Belge Mixed-Use Renovation – Brussels Capital
Equip yourself with the essential tools needed to make informed and profitable decisions with our APE/ Cores Dev/ Foresite/ Urbicoon - Royale Belge Mixed-Use Renovation - Brussels Capital report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
-
Company Profile
NewORIC Pharmaceuticals Inc – Company Profile
ORIC Pharmaceuticals Inc (ORIC) is a clinical-stage pharmaceutical company. It focuses on therapies to treat cancer. The company’s pipeline product pipeline includes ORIC-533, a orally bioavailable small molecule inhibitor for treatment of multiple myeloma; ORIC-114 to treat non-small cell lung cancer and breast and tumor agnostic; and ORIC-944 to treat prostate cancer. It is also developing multiple drug programs for therapeutic areas of breast cancer, and solid tumors. ORIC is headquartered in South San Francisco, California, the US.
Add to Basket -
Track & Monitor
Coronavirus Disease (COVID-19) Impact on Biopharmaceutical Venture Capital Deals
This report examines the impact of the COVID-19 pandemic on venture capital deals for biopharmaceutical companies. This analysis is critical to understanding how the outbreak of COVID-19 impacted investments and how those VC deal trends may impact current and future venture capital investments.